166 related articles for article (PubMed ID: 21555715)
1. Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: results from the E3N cohort.
Engel P; Fabre A; Fournier A; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F
Am J Epidemiol; 2011 Jul; 174(1):12-21. PubMed ID: 21555715
[TBL] [Abstract][Full Text] [Related]
2. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study.
Canonico M; Fournier A; Carcaillon L; Olié V; Plu-Bureau G; Oger E; Mesrine S; Boutron-Ruault MC; Clavel-Chapelon F; Scarabin PY
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):340-5. PubMed ID: 19834106
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and Older: results from the National Osteoporosis Risk Assessment (NORA).
Siris ES; Brenneman SK; Miller PD; Barrett-Connor E; Chen YT; Sherwood LM; Abbott TA
J Bone Miner Res; 2004 Aug; 19(8):1215-20. PubMed ID: 15231007
[TBL] [Abstract][Full Text] [Related]
4. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment.
Yates J; Barrett-Connor E; Barlas S; Chen YT; Miller PD; Siris ES
Obstet Gynecol; 2004 Mar; 103(3):440-6. PubMed ID: 14990403
[TBL] [Abstract][Full Text] [Related]
5. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review.
Fournier A
Menopause Int; 2010 Mar; 16(1):23-32. PubMed ID: 20424283
[TBL] [Abstract][Full Text] [Related]
6. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort: an analysis from the Manitoba Bone Density Program.
Hodsman AB; Leslie WD; Tsang JF; Gamble GD
Arch Intern Med; 2008 Nov; 168(20):2261-7. PubMed ID: 19001204
[TBL] [Abstract][Full Text] [Related]
7. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women.
Antoniucci DM; Sellmeyer DE; Cauley JA; Ensrud KE; Schneider JL; Vesco KK; Cummings SR; Melton LJ;
J Bone Miner Res; 2005 May; 20(5):741-7. PubMed ID: 15824846
[TBL] [Abstract][Full Text] [Related]
8. Nulliparity and fracture risk in older women: the study of osteoporotic fractures.
Hillier TA; Rizzo JH; Pedula KL; Stone KL; Cauley JA; Bauer DC; Cummings SR
J Bone Miner Res; 2003 May; 18(5):893-9. PubMed ID: 12733729
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women.
Grodstein F; Stampfer MJ; Falkeborn M; Naessen T; Persson I
Epidemiology; 1999 Sep; 10(5):476-80. PubMed ID: 10468418
[TBL] [Abstract][Full Text] [Related]
10. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.
Colditz GA; Hankinson SE; Hunter DJ; Willett WC; Manson JE; Stampfer MJ; Hennekens C; Rosner B; Speizer FE
N Engl J Med; 1995 Jun; 332(24):1589-93. PubMed ID: 7753136
[TBL] [Abstract][Full Text] [Related]
11. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group.
Cummings SR; Browner WS; Bauer D; Stone K; Ensrud K; Jamal S; Ettinger B
N Engl J Med; 1998 Sep; 339(11):733-8. PubMed ID: 9731089
[TBL] [Abstract][Full Text] [Related]
12. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors.
Fabre A; Fournier A; Mesrine S; Gompel A; Desreux J; Berrino F; Boutron-Ruault MC; Romieu I; Clavel-Chapelon F
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2723-8. PubMed ID: 18843015
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
14. The relationship between back pain and future vertebral fracture in postmenopausal women.
Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
[TBL] [Abstract][Full Text] [Related]
15. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women.
Tamimi RM; Hankinson SE; Chen WY; Rosner B; Colditz GA
Arch Intern Med; 2006 Jul; 166(14):1483-9. PubMed ID: 16864758
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
17. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
18. Association of total calcium and dietary protein intakes with fracture risk in postmenopausal women: the 1999-2002 National Health and Nutrition Examination Survey (NHANES).
Zhong Y; Okoro CA; Balluz LS
Nutrition; 2009 Jun; 25(6):647-54. PubMed ID: 19230618
[TBL] [Abstract][Full Text] [Related]
19. Hormone therapy use among postmenopausal French women before the publication of the Women's Health Initiative study: duration of use and factors associated with discontinuation.
Ringa V; Varnoux N; Piault S; Bréart G
Fertil Steril; 2005 Jun; 83(6):1771-9. PubMed ID: 15950650
[TBL] [Abstract][Full Text] [Related]
20. Changes of menopausal hormone therapy use pattern since 2000: results of the Berlin Spandau Longitudinal Health Study.
Du Y; Scheidt-Nave C; Schaffrath Rosario A; Ellert U; Dören M; Knopf H
Climacteric; 2009 Aug; 12(4):329-40. PubMed ID: 19437194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
